Hemorrhagic Stroke

🩺What is Hemorrhagic Stroke?

The National Institutes of Health Stroke Scale (NIHSS) was originally developed by Brott, Adams, and colleagues in 1989 as a research tool to standardize the measurement of neurological deficit severity in acute stroke clinical trials. It was later refined by Lyden et al. in 1994 and has since evolved into the standard clinical instrument for acute stroke assessment worldwide. The full NIHSS comprises 15 items evaluating level of consciousness, gaze, visual fields, facial palsy, motor arm and leg function, limb ataxia, sensory function, language, dysarthria, and extinction/inattention. This simplified version includes 11 core items, grouping motor arm and leg scores by combining both sides. Each item is graded on an ordinal scale from 0 (normal) to 2, 3, or 4 (most severe), with the motor components allowing up to 8 points when both sides are affected. Total scores range from 0 (no deficit) to 42 (most severe deficit). The NIHSS has been extensively validated across diverse populations and is used in all major stroke trials as the standard outcome measure. It shows high inter-rater reliability after formal certification and is sensitive to clinically meaningful changes in neurological status. The scale is endorsed by the American Heart Association/American Stroke Association (AHA/ASA), the European Stroke Organisation, and the World Stroke Organization. The NIHSS is fundamental to treatment decisions — it identifies candidates for intravenous thrombolysis and endovascular thrombectomy and tracks neurological improvement or deterioration during hospitalization.

🏥Signs & Symptoms

The following clinical signs and symptoms are commonly assessed when evaluating Hemorrhagic Stroke:

• Level of Consciousness
• Gaze / Oculomotor
• Visual Fields
• Facial Palsy
• Motor Arm (both sides combined)
• Motor Leg (both sides combined)
• Ataxia / Limb Coordination
• Sensory / Pinprick
• Language / Naming
• Dysarthria / Speech Clarity
• Extinction / Inattention
• mRS Grade

🔬Causes & Etiology

The National Institutes of Health Stroke Scale (NIHSS) was originally developed by Brott, Adams, and colleagues in 1989 as a research tool to standardize the measurement of neurological deficit severity in acute stroke clinical trials. It was later refined by Lyden et al. in 1994 and has since evolved into the standard clinical instrument for acute stroke assessment worldwide. The full NIHSS comprises 15 items evaluating level of consciousness, gaze, visual fields, facial palsy, motor arm and leg function, limb ataxia, sensory function, language, dysarthria, and extinction/inattention. This simplified version includes 11 core items, grouping motor arm and leg scores by combining both sides. Each item is graded on an ordinal scale from 0 (normal) to 2, 3, or 4 (most severe), with the motor components allowing up to 8 points when both sides are affected. Total scores range from 0 (no deficit) to 42 (most severe deficit). The NIHSS has been extensively validated across diverse populations and is used in all major stroke trials as the standard outcome measure. It shows high inter-rater reliability after formal certification and is sensitive to clinically meaningful changes in neurological status. The scale is endorsed by the American Heart Association/American Stroke Association (AHA/ASA), the European Stroke Organisation, and the World Stroke Organization. The NIHSS is fundamental to treatment decisions — it identifies candidates for intravenous thrombolysis and endovascular thrombectomy and tracks neurological improvement or deterioration during hospitalization.

The mRS is a 7-level scale (0-6) that measures functional independence after stroke. Grade 0 = no symptoms, Grade 5 = severe disability (bedridden), Grade 6 = death. It is the primary endpoint in most acute stroke trials and is recommended by the AHA/ASA for standardized outcome assessment.

📊Clinical Assessment & Risk Scoring

Healthcare professionals use these validated clinical calculators, diagnostic scales, and risk scoring systems to assess the severity, prognosis, or therapeutic dosing requirements for Hemorrhagic Stroke:

• NIH Stroke Scale Calculator

  The NIH Stroke Scale (NIHSS) is a systematic assessment tool used to quantify the severity of stroke-related neurological deficits. It is widely used in acute stroke settings to guide treatment decisions.

• Modified Rankin Scale (mRS) for Stroke Disability

  The Modified Rankin Scale (mRS) is the most widely used outcome measure for stroke clinical trials and clinical practice, measuring the degree of disability in daily activities.

🧬Diagnostic Logic & Scoring Breakdown

The NIHSS is calculated by summing the scores from all assessed items, each representing a distinct neurological domain. Level of consciousness (0-3) assesses overall alertness: 0 for alert, 1 for drowsy but arousable, 2 for obtunded requiring repeated stimulation, and 3 for coma with no response. Gaze (0-2) evaluates horizontal eye movement: 0 for normal, 1 for partial gaze palsy, and 2 for forced deviation or total palsy. Visual fields (0-3) test each quadrant: 0 for no loss, 1 for partial hemianopia, 2 for complete hemianopia, and 3 for bilateral hemianopia or cortical blindness. Facial palsy (0-3) assesses lower and upper face weakness: 0 for normal, 1 for minor asymmetry, 2 for partial lower face weakness, and 3 for complete unilateral or bilateral paralysis. Motor arm (0-8) combines both arms: tested with arms held at 45° (supine) or 90° (sitting) for 10 seconds — drift in one arm scores 2, drift in both scores 4, some effort scores 6, and no effort scores 8. Motor leg (0-8) similarly combines both legs with the leg held at 30° for 5 seconds. Limb ataxia (0-2) tests finger-to-nose and heel-to-shin for cerebellar dysfunction. Sensory (0-2) evaluates pinprick sensation on the face, arm, trunk, and leg. Language (0-3) assesses naming, fluency, and comprehension through picture description and object naming. Dysarthria (0-2) evaluates speech articulation clarity. Extinction/inattention (0-2) tests simultaneous bilateral stimulation. Each item contributes incrementally to a maximum total of 42 points. In general, scores of 0-4 indicate minor stroke, 5-15 moderate stroke, 16-20 moderate-severe stroke, and 21-42 severe stroke. Serial NIHSS assessments are critical: a decrease of 4 or more points indicates significant improvement, while an increase of 4 or more points signals neurological deterioration.

📢Clinical Significance & Implications

The NIHSS is the reference standard for acute stroke assessment and is incorporated into all major stroke treatment guidelines, including the American Heart Association/American Stroke Association (AHA/ASA) 2019 Guidelines for the Early Management of Acute Ischemic Stroke and the European Stroke Organisation (ESO) guidelines. The baseline NIHSS score at presentation is the single strongest predictor of 90-day functional outcome, with a score of 0-4 predicting good recovery in over 80% of patients, while scores above 15 predict poor functional outcomes. The NIHSS guides critical treatment decisions: patients with NIHSS ≥ 4 are generally considered candidates for intravenous thrombolysis with alteplase within 4.5 hours of symptom onset, though some guidelines also consider patients with NIHSS < 4 who have disabling deficits. Patients with NIHSS ≥ 6 and evidence of large vessel occlusion on CT angiography are typically candidates for mechanical thrombectomy, particularly if within 6 hours of onset, extended to 24 hours with advanced perfusion imaging (DAWN and DEFUSE-3 criteria). Serial NIHSS assessments during the first 24 hours are highly prognostic: improvement of 4 or more points correlates with recanalization, while worsening signals hemorrhagic transformation, edema progression, or reocclusion. The NIHSS is also used as a stratification tool in clinical trials, as a measure of stroke severity for hospital benchmarking, and to identify patients needing ICU-level monitoring. However, the NIHSS has limitations: it is heavily weighted toward left hemisphere functions (language), underestimates posterior circulation stroke severity, and is less sensitive for mild or right hemisphere deficits. The modified NIHSS (mNIHSS) and shortened versions address some of these limitations.

🛡️Prevention & Management

Evidence-based prevention and management strategies for Hemorrhagic Stroke include:

• Monitor for neurological deterioration, perform stroke workup (imaging, labs), and initiate secondary prevention.
• Admit to stroke unit or ICU, neurology consultation, consider thrombolysis if within therapeutic window, close neurological monitoring, and swallow evaluation.
• ICU admission, urgent neurology/neurosurgery consultation, consider advanced interventions (thrombectomy), frequent NIHSS reassessment, and discuss prognosis with family.
• Excellent outcome. No specific intervention needed beyond standard secondary prevention.
• Good outcome. Outpatient follow-up and secondary prevention.
• Mild disability. Consider outpatient rehabilitation and secondary prevention.
• The mRS measures functional disability/outcome (how much assistance the patient needs for daily activities) and is assessed at discharge or follow-up (typically 90 days). NIHSS measures acute neurological deficit severity (specific neurological exam findings) and is assessed at presentation and during the first 24-72 hours. They serve different purposes: mRS for outcome measurement, NIHSS for acute severity assessment and treatment decisions.

⚡Complications & Prognosis

Without proper management, Hemorrhagic Stroke may lead to the following complications:

The NIHSS is the reference standard for acute stroke assessment and is incorporated into all major stroke treatment guidelines, including the American Heart Association/American Stroke Association (AHA/ASA) 2019 Guidelines for the Early Management of Acute Ischemic Stroke and the European Stroke Organisation (ESO) guidelines. The baseline NIHSS score at presentation is the single strongest predictor of 90-day functional outcome, with a score of 0-4 predicting good recovery in over 80% of patients, while scores above 15 predict poor functional outcomes. The NIHSS guides critical treatment decisions: patients with NIHSS ≥ 4 are generally considered candidates for intravenous thrombolysis with alteplase within 4.5 hours of symptom onset, though some guidelines also consider patients with NIHSS < 4 who have disabling deficits. Patients with NIHSS ≥ 6 and evidence of large vessel occlusion on CT angiography are typically candidates for mechanical thrombectomy, particularly if within 6 hours of onset, extended to 24 hours with advanced perfusion imaging (DAWN and DEFUSE-3 criteria). Serial NIHSS assessments during the first 24 hours are highly prognostic: improvement of 4 or more points correlates with recanalization, while worsening signals hemorrhagic transformation, edema progression, or reocclusion. The NIHSS is also used as a stratification tool in clinical trials, as a measure of stroke severity for hospital benchmarking, and to identify patients needing ICU-level monitoring. However, the NIHSS has limitations: it is heavily weighted toward left hemisphere functions (language), underestimates posterior circulation stroke severity, and is less sensitive for mild or right hemisphere deficits. The modified NIHSS (mNIHSS) and shortened versions address some of these limitations.

💡 Clinical Assessment Scenario Example

A 65-year-old right-handed male with atrial fibrillation (not on anticoagulation) and hypertension presents to the emergency department 90 minutes after sudden onset of right-sided weakness, inability to speak, and left gaze deviation. His family reports he was last seen normal 90 minutes ago. On examination, blood pressure is 155/92 mmHg, heart rate is 110 bpm and irregular, and glucose is 105 mg/dL. NIHSS assessment: Level of consciousness — the patient is drowsy but opens eyes to voice (LOC = 1). Gaze — there is forced gaze deviation to the left (Gaze = 2). Visual fields — unable to fully assess due to gaze deviation, but no clear hemianopia on confrontation (Visual = 0). Facial palsy — right lower face is weak with flattened nasolabial fold (Facial = 2). Motor arm — left arm extends fully with no drift (0), right arm drifts downward within 10 seconds (2); combined motor arm = 2. Motor leg — left leg no drift (0), right leg drifts within 5 seconds (2); combined motor leg = 2. Ataxia — no cerebellar signs (0). Sensory — decreased pinprick on the right arm and leg (Sensory = 1). Language — the patient produces only incomprehensible sounds and cannot follow one-step commands (Language = 2). Dysarthria — slurred speech but can be understood (Dysarthria = 1). Extinction — no neglect on double simultaneous stimulation (0). Total NIHSS = 1+2+0+2+2+2+0+1+2+1+0 = 13 out of 42, representing a moderate stroke (NIHSS 5-15). Given presentation within the thrombolytic window (<4.5 hours) and NIHSS ≥ 4, the patient is a candidate for IV alteplase after excluding contraindications. Non-contrast CT head shows no hemorrhage, and CT angiography reveals a left middle cerebral artery M1 segment occlusion. The patient receives IV alteplase and is transferred for mechanical thrombectomy given large vessel occlusion with NIHSS ≥ 6.

💊Common Medications & Interventions

The following pharmacological therapies and substances are commonly referenced or adjusted based on the clinical assessment of Hemorrhagic Stroke:

🔗Related Diseases & Conditions

These conditions are clinically associated with Hemorrhagic Stroke through shared risk-scoring calculators and assessment tools:

• Ischemic Stroke
• Transient Ischemic Attack

⚠️Clinical Assessment Pitfalls

• ❌ Mistake: Not scoring both sides separately for motor arm and leg

  ✅ Correction: Motor arm and leg scores combine both sides. If one side is weak, use the higher score for that side.

• ❌ Mistake: Using NIHSS as the sole prognostic tool

  ✅ Correction: NIHSS should be combined with age, comorbidities, CT/MRI findings, and time from onset for accurate prognosis.

• ❌ Mistake: Not accounting for aphasia when scoring other items

  ✅ Correction: Patients with aphasia may not understand commands. Use visual cues, mimed commands, or score based on best effort.

• ❌ Mistake: Performing NIHSS too quickly without proper training

  ✅ Correction: Formal NIHSS certification is recommended through AHA/ASA or the National Institutes of Health. Proper training ensures reliable and reproducible scoring.

• ❌ Mistake: Failing to assess extinction/inattention properly

  ✅ Correction: Extinction is tested by simultaneous bilateral stimulation. Do not skip this item — it can be positive even when sensory and visual scores are normal and indicates parietal lobe dysfunction.

• ❌ Mistake: Confusing mRS with NIHSS (NIH Stroke Scale)

  ✅ Correction: NIHSS measures neurological deficit severity (acute assessment), while mRS measures functional disability/outcome (typically assessed at discharge, 90 days, or longer follow-up). They measure different constructs.

• ❌ Mistake: Assessing mRS too early after stroke

  ✅ Correction: The mRS is designed as an outcome measure, not an acute assessment tool. Standard assessment timepoints are at discharge, 90 days, and 1 year post-stroke. Early assessment (within 24-48 hours) may not reflect final functional outcome.

🚑When to Seek Medical Attention

This reference supports clinical assessment of Hemorrhagic Stroke; it does not replace urgent evaluation. Seek prompt in-person medical care if symptoms are severe, rapidly worsening, or life-threatening, or if you are unsure about a diagnosis or treatment plan. Patients should always consult their physician before starting or changing any therapy.

❓Frequently Asked Questions

📚Evidence-Based References